A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate if the addition of Bortezomib (Velcade) to IGEV
combination (Ifosfamide, Gemcitabine and Vinorelbine) in patients with relapsed/refractory
Hodgkin's lymphoma increases the rate of complete remission (PET negativity) at
transplantation.